Twist Bioscience Corporation

NasdaqGS TWST

Twist Bioscience Corporation Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -66.69%

Twist Bioscience Corporation Net Income Margin is -66.69% for the Trailing 12 Months (TTM) ending September 30, 2024, a 20.11% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Twist Bioscience Corporation Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -83.48%, a 22.00% change year over year.
Twist Bioscience Corporation Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -107.02%, a 6.88% change year over year.
Twist Bioscience Corporation Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -114.93%, a 26.00% change year over year.
Twist Bioscience Corporation Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -155.31%, a 21.55% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGS: TWST

Twist Bioscience Corporation

CEO	Dr. Emily Marine Leproust Ph.D.
IPO Date	Oct. 31, 2018
Location	United States
Headquarters	681 Gateway Boulevard
Employees	919
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Key trends

Past 5 years